All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, February 5, 2023
Breaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeks
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Colorful illustration of the heart
Biomarkers

Plasmatic GAS6 levels predict acute heart failure mortality risk

Jan. 27, 2023
No Comments
Heart failure still remains a leading cause of death worldwide. Improving risk stratification and prognostic analysis tools is required to aid in the management of the disease.
Read More
Immuno-oncology

Sana receives IND clearance for CAR T-cell therapy SC-291 for B-cell malignancies

Jan. 27, 2023
No Comments
Sana Biotechnology Inc. has received FDA clearance of its IND application to initiate a first-in-human study of SC-291 in patients with various B-cell malignancies. Initial clinical data from the study are expected later this year. SC-291 is a CD19-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy developed using Sana's hypoimmune platform.
Read More
Gastrointestinal

Exegi Pharma cleared to study EXE-346 for management of IPAA patients

Jan. 27, 2023
No Comments
Exegi Pharma LLC has received FDA clearance of its IND application for EXE-346, allowing the company to initiate a clinical trial to evaluate EXE-346 in the management of excessive stool frequency in patients with an ileal pouch-anal anastomosis (IPAA, J-Pouch).
Read More
Brain and DNA
Neurology/Psychiatric

Herophilus conducts in vivo studies of HRP-12975 for Rett syndrome

Jan. 27, 2023
No Comments
Herophilus Inc. is conducting in vivo studies of lead candidate HRP-12975, a small-molecule therapy for Rett syndrome, with funding from the Rett Syndrome Research Trust. The company is generating efficacy and safety data with HRP-12975 using genetic mouse models of Rett syndrome.
Read More
Inflammatory

Novel anti-inflammatory compound alleviates LPS-induced acute lung injury in vivo

Jan. 27, 2023
No Comments
Researchers from Wenzhou Medical University and affiliated organizations have reported the discovery and preclinical evaluation of novel anti-inflammatory compounds. Synthesis and optimization of a new series of 1-(4-(benzylsulfonyl)-2-nitrophenyl) derivatives resulted in the identification of compound [I] as the lead candidate.
Read More
Illustration of antibodies attacking nerve cells
Neurology/Psychiatric

Lapix receives support from FDA for IND-enabling plan for LPX-TI641

Jan. 27, 2023
No Comments
Lapix Therapeutics Inc. has announced the successful outcome of its pre-IND meeting request with the FDA to achieve alignment on the company's IND-enabling plan for LPX-TI641, being developed for neuro-autoimmune indications such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein antibody disease (MOGAD).
Read More
Mouse retina.
Ocular

CU06-1004 shows efficacy in animal models of retinal vascular diseases

Jan. 27, 2023
No Comments
Researchers from Curacle Co. Ltd. and Yonsei University have published preclinical data for the endothelial dysfunction blocker CU06-1004 from studies assessing it in models of retinal vascular disease.
Read More
Immuno-oncology

Roquefort's ROQ-A1 and ROQ-A2 Midkine antibody programs demonstrate in vivo safety

Jan. 27, 2023
No Comments
Roquefort Therapeutics plc's ROQ-A1 and ROQ-A2 Midkine (MDK) antibody programs, targeting metastatic breast cancer and metastatic lung cancer, have successfully demonstrated in vivo safety in preclinical development programs conducted by cancer research groups.
Read More
Neutrophil and red blood cells
Cancer

Redeeming neutrophils could be anticancer approach

Jan. 27, 2023
By Mar de Miguel
No Comments
Unexpected behavior of neutrophils unveiled by researchers at Stanford University could lead to a new type of immunotherapy to treat cancer. Although various studies have suggested that these cells are harmful due to their immunosuppressive characteristics, the scientists saw in them an opportunity to redirect them and eliminate tumors.
Read More

Other news to note for Jan. 26, 2023

Jan. 26, 2023
No Comments
Additional early-stage research and drug discovery news in brief, from: Allogene, Clostrabio, Inhibikase, Inmune, Storm, Trethera.
Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 16874 16875 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 3, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Feb. 3, 2022.
  • Setpoint Medical - vagus nerve stimulation device

    Setpoint Medical lands up to $145M to advance RA implant

    BioWorld MedTech
    Bioelectronic medicine startup Setpoint Medical Corp. raised $80 million in a preferred stock financing co-led by new investors Norwest Venture Partners and...
  • Brain with clock hands, day and night background

    12-Hour as well as circadian brain rhythms disrupted in people with schizophrenia

    BioWorld Science
    Research shows that individuals with schizophrenia have abnormal gene expression patterns in their brains compared with people without the condition. In a study...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing